Shares in Value Logo
Product Review Img Vertical

Date : 18/02/2021

Learn why Medlab (ASX:MDC) joined hands with Australia’s largest OTC supplier

Medlab (ASX: MDC) is a biotech company with a portfolio of novel medicinal candidates enhanced by its delivery platform and used for the treatment of chronic pain and disease. The firm announced that it has entered into an exclusive non-binding Heads of Agreement (HoA) with Australia’s largest generic pharmaceutical and over the counter (OTC) medicines company, Arrotex Australia Group Australia Pty Ltd. The agreement will enable the development and distribution of NanoCBD to Australian pharmacies.

The HoA is the first partnership between a pharma and a biotech investigating medical cannabis in Australia. The cannabis market is very hot right now and there are quite a few opportunities that are popping up for the top ASX cannabis stocks. This partnership sets Medlab apart in a market that is adjusting to new opportunities presented by over the counter (OTC) sales of eligible TGA approved medicines. The HoA will enable a faster development for the clinical package that is required for the final lodgement of an application to the TGA .

The definitive agreement including commercial terms will be finalised on or before 1 July 2021. Following the announcement, MDC shares moved up on the ASX and were trading at A$0.340 up by 4.615% at AEDT 12:15 PM.

NanoCBD™ to be Distributed by Medlab to Australian Pharmacies

Arrotex is Australia’s largest generic pharmaceutical and private label over the counter (OTC) medicines company with extensive experience in the TGA application process. Supported by the largest sales force in the Australian pharmaceutical industry, the company supplies the medicines which make up 85% of all prescriptions written by Australian doctors and found in every Australian pharmacy. This makes them an ideal partner for Medlab to distribute NanoCBD to Australian pharmacies.

Looking for Growth Stocks?

Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.

 

Are You Looking To Buy The Best Stocks In 2022?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2022!

 

Top 5 ASX Stocks
to Buy for Capital Growth in 2022

asx landing page
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.

Download Your Free Report

By downloading this report you agree to the TERMS AND CONDITIONS and our PRIVACY POLICY

Scroll to Top

Login

By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Please fill in your details to download the free dividend shares report.

We will send your report instantly. Please put your correct email address and phone number.